Bayer (Peru) Past Earnings Performance
Past criteria checks 1/6
Bayer (Peru)'s earnings have been declining at an average annual rate of -23.1%, while the Pharmaceuticals industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 2.8% per year. Bayer (Peru)'s return on equity is 7.2%, and it has net margins of 3.6%.
Key information
-23.1%
Earnings growth rate
-23.1%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 2.8% |
Return on equity | 7.2% |
Net Margin | 3.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bayer (Peru) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 338 | 12 | 80 | 0 |
30 Sep 23 | 339 | 4 | 85 | 0 |
30 Jun 23 | 344 | -3 | 86 | 0 |
31 Mar 23 | 336 | 0 | 83 | 0 |
31 Dec 22 | 376 | 27 | 83 | 0 |
30 Sep 22 | 364 | 12 | 80 | 0 |
30 Jun 22 | 385 | 21 | 79 | 0 |
31 Mar 22 | 403 | 29 | 82 | 0 |
31 Dec 21 | 381 | 20 | 80 | 0 |
30 Sep 21 | 388 | 40 | 75 | 0 |
30 Jun 21 | 387 | 51 | 75 | 0 |
31 Mar 21 | 363 | 44 | 73 | 0 |
31 Dec 20 | 328 | 37 | 74 | 0 |
30 Sep 20 | 331 | 50 | 73 | 0 |
30 Jun 20 | 313 | 46 | 72 | 0 |
31 Mar 20 | 303 | 35 | 76 | 0 |
31 Dec 19 | 292 | 25 | 79 | 0 |
30 Sep 19 | 324 | 29 | 85 | 0 |
30 Jun 19 | 315 | 21 | 89 | 0 |
31 Mar 19 | 330 | 34 | 91 | 0 |
31 Dec 18 | 338 | 38 | 95 | 0 |
30 Sep 18 | 313 | 31 | 89 | 0 |
30 Jun 18 | 330 | 44 | 87 | 0 |
31 Mar 18 | 327 | 40 | 87 | 0 |
31 Dec 17 | 347 | 46 | 89 | 0 |
30 Sep 17 | 351 | 32 | 101 | 0 |
30 Jun 17 | 361 | 23 | 109 | 0 |
31 Mar 17 | 387 | 24 | 112 | 0 |
31 Dec 16 | 408 | 29 | 109 | 0 |
30 Sep 16 | 419 | 11 | 112 | 0 |
30 Jun 16 | 425 | 14 | 106 | 0 |
31 Mar 16 | 418 | 17 | 106 | 0 |
31 Dec 15 | 419 | 18 | 103 | 0 |
30 Sep 15 | 397 | 33 | 99 | 0 |
30 Jun 15 | 382 | 36 | 98 | 0 |
31 Mar 15 | 368 | 30 | 98 | 0 |
31 Dec 14 | 339 | 15 | 104 | 0 |
30 Sep 14 | 333 | 20 | 100 | 0 |
30 Jun 14 | 322 | 14 | 101 | 0 |
31 Mar 14 | 323 | 13 | 103 | 0 |
31 Dec 13 | 336 | 18 | 105 | 0 |
30 Sep 13 | 340 | 25 | 105 | 0 |
30 Jun 13 | 336 | 23 | 106 | 0 |
Quality Earnings: BAYERI1 has high quality earnings.
Growing Profit Margin: BAYERI1's current net profit margins (3.6%) are lower than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAYERI1's earnings have declined by 23.1% per year over the past 5 years.
Accelerating Growth: BAYERI1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BAYERI1 had negative earnings growth (-54.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.2%).
Return on Equity
High ROE: BAYERI1's Return on Equity (7.2%) is considered low.